Alzheimer disease (AD) is a neurodegenerative disease that is characterized by brain accumulation of β-amyloid (Aβ) and tau, progressive atrophy, and cognitive decline. Biomarkers that capture biological processes in AD are increasingly used to support the diagnosis of AD in research, drug development, and clinical practice.
1 The most well-established AD biomarkers include structural magnetic resonance imaging (MRI); cerebrospinal fluid (CSF) biomarkers of Aβ, tau, and neuronal injury; and positron emission tomographic imaging of Aβ, tau, and brain metabolism.
2-4 Use of these biomarkers is hampered by a high degree of invasiveness, high costs, or limited availability.
5 Blood-based biomarkers for AD may allow for efficient monitoring of disease processes in AD and could be used as a screening tool in primary care. One potential blood-based biomarker for AD is the neuronal injury marker neurofilament light (NFL)
6 because patients with AD have increased CSF concentrations of NFL.
7 Results from some studies
8,9 suggest that patients with AD have increased plasma NFL concentrations. However, those studies were performed using standard immunoassay techniques with suboptimal analytical sensitivity to accurately quantify low abundant brain-specific proteins in blood samples.
10 For this reason, our group has recently transferred the CSF NFL assay to an ultrasensitive single-molecule array (Simoa; Quanterix Corporation) platform, which provides an analytical sensitivity of 0.6 pg/mL compared with 78.0 pg/mL for the corresponding enzyme-linked immunosorbent assay (ELISA).
10 Plasma NFL concentrations can be measured in all samples using the ultrasensitive single-molecule array and correlate closely with the corresponding CSF concentrations.
11,12 Herein, we test this novel plasma NFL assay in patients with AD for the first time, to our knowledge. We studied cognitively healthy control individuals, patients with mild cognitive impairment (MCI) (MCI group), and patients with AD dementia (AD group) in a large prospective study. We tested the hypotheses that the plasma NFL concentration is increased in AD and that it correlates with impaired cognition, neuroimaging abnormalities, and CSF biomarkers of AD pathologic features.